Abstract
The recent research area endeavors to discover ultimate multi-target ligands, an increasingly feasible and attractive alternative to existing mono-targeted drugs for treatment of complex, multi-factorial inflammation process which underlays plethora of debilitated health conditions. In order to improvise this option, exploration of relevant chemical core scaffold will be an utmost need. Privileged benzimidazole scaffold being historically versatile structural motif could offer a viable starting point in the search for novel multi-target ligands against multi-factorial inflammation process since, when appropriately substituted, it can selectively modulate diverse receptors, pathways and enzymes associated with the pathogenesis of inflammation. Despite this remarkable capability, the multi-target capacity of the benzimidazole scaffold remains largely unexploited. With this in focus, the present review article attempts to provide synopsis of published research to exemplify the valuable use of benzimidazole nucleus and focus on their suitability as starting scaffold to develop multi-targeted anti-inflammatory ligands.
Keywords: Anti-inflammatory drug targets, inflammation, multi-factorial, multi-target ligand, privileged scaffold.
Mini-Reviews in Medicinal Chemistry
Title:Benzimidazoles: An Ideal Privileged Drug Scaffold for the Design of Multitargeted Anti-inflammatory Ligands
Volume: 14 Issue: 9
Author(s): Gaganpreet Kaur, Maninder Kaur and Om Silakari
Affiliation:
Keywords: Anti-inflammatory drug targets, inflammation, multi-factorial, multi-target ligand, privileged scaffold.
Abstract: The recent research area endeavors to discover ultimate multi-target ligands, an increasingly feasible and attractive alternative to existing mono-targeted drugs for treatment of complex, multi-factorial inflammation process which underlays plethora of debilitated health conditions. In order to improvise this option, exploration of relevant chemical core scaffold will be an utmost need. Privileged benzimidazole scaffold being historically versatile structural motif could offer a viable starting point in the search for novel multi-target ligands against multi-factorial inflammation process since, when appropriately substituted, it can selectively modulate diverse receptors, pathways and enzymes associated with the pathogenesis of inflammation. Despite this remarkable capability, the multi-target capacity of the benzimidazole scaffold remains largely unexploited. With this in focus, the present review article attempts to provide synopsis of published research to exemplify the valuable use of benzimidazole nucleus and focus on their suitability as starting scaffold to develop multi-targeted anti-inflammatory ligands.
Export Options
About this article
Cite this article as:
Kaur Gaganpreet, Kaur Maninder and Silakari Om, Benzimidazoles: An Ideal Privileged Drug Scaffold for the Design of Multitargeted Anti-inflammatory Ligands, Mini-Reviews in Medicinal Chemistry 2014; 14 (9) . https://dx.doi.org/10.2174/1389557514666140820120518
DOI https://dx.doi.org/10.2174/1389557514666140820120518 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets The Mechanism in Gastric Cancer Chemoprevention by Allicin
Anti-Cancer Agents in Medicinal Chemistry High-level Soluble Expression, Purification, and Functional Characterization of the Recombinant Human Leukemia Inhibitory Factor: A Potential General Strategy for the Recombinant Expression of Cytokines Consisting of Four α-Helices in a Bundle
Protein & Peptide Letters Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept
Current Cancer Drug Targets The Molecular Machinery Regulating Apoptosis Signal Transduction and its Implication in Human Physiology and Pathophysiologies
Current Molecular Medicine Liver Stem Cells and Possible Clinical Applications
Current Stem Cell Research & Therapy Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery <i>In Silico</i> Docking Studies of Vascular Endothelial Growth Factor-A (VEGFA): Possible Implications in Chronic Myeloid Leukemia (CML) Therapy
Current Proteomics miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Novel Approaches for RNA Interference and their Application in Cancer Therapy
Current Pharmacogenomics Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
Current Cancer Drug Targets Equilibrative Nucleoside Transporters in Fetal Endothelial Dysfunction in Diabetes Mellitus and Hyperglycaemia
Current Vascular Pharmacology The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy
Current Signal Transduction Therapy Higher Levels of Dynamin-related Protein 1 are Associated with Reduced Radiation Sensitivity of Glioblastoma Cells
Current Neurovascular Research Targeting the Perpetrator: Breast Cancer Stem Cell Therapeutics
Current Drug Targets Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions?
Current Drug Metabolism Pentapeptides as Minimal Functional Units in Cell Biology and Immunology
Current Protein & Peptide Science Reduction in Ischemic Cerebral Infarction is Mediated through Golgi Phosphoprotein 3 and Akt/mTOR Signaling Following Salvianolate Administration
Current Neurovascular Research The Involvement of Post-Translational Modifications in Alzheimer's Disease
Current Alzheimer Research Development of Decision Tree Models for Substrates, Inhibitors, and Inducers of P-Glycoprotein
Current Drug Metabolism